James M. Frates, Director at Sage Therapeutics, Inc. (SAGE), sold 9,200 shares at $160.58 ($1.3M) on 2019-08-15, disclosed to the SEC on 2019-08-16.
Open-market sale of $1.3M SAGE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,200 | $0 | 0.0% |
| 2 | $160.58 | 8,000 | $1.3M | 100.0% |
| Total | $139.63 avg | 9,200 | $1.3M | 100% |
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |